RADICAVA
PeakNDAINTRAVENOUSSOLUTION
Approved
May 2017
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
5/8 — Partial
RADICAVA by Tanabe Pharma America is 12. Approved for amyotrophic lateral sclerosis (als). First approved in 2017.
Drug data last refreshed 10h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
RADICAVA (edaravone) is a small-molecule intravenous infusion approved for amyotrophic lateral sclerosis (ALS), a progressive neurodegenerative disease. The exact mechanism of action remains unknown, though the drug demonstrates a trend toward slowing disease progression in ALS patients. It is administered as a 60 mg IV infusion and has an oral formulation (RADICAVA ORS) with 57% bioavailability.
$0.011BPart D
PeakRADICAVA is in peak lifecycle stage with modest Medicare spending ($11M in 2023), suggesting a mature, niche-market product with stable but limited commercial growth potential.
Mechanism of Action
12.1 Mechanism of Action The mechanism by which RADICAVA and RADICAVA ORS exert their therapeutic effect in patients with ALS is unknown. 12.2 Pharmacodynamics Cardiac Electrophysiology At exposures at least 5 times higher than that of the recommended doses of RADICAVA and RADICAVA ORS, edaravone…
Worked on RADICAVA at Tanabe Pharma America? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.